Brett Heavner gives us the lowdown on the FDA regulations and the Lanham Act’s false advertising rules, both of which are vital when it comes to pharmaceutical marketing. Direct-to-consumer ...

The FDA has issued a complete response letter (CRL) to Spectrum Pharma for poziotinib, its pan HER2 inhibitor for a form of lung cancer, according to South Korea's Hanmi Pharma, which originally ...